低级别胶质瘤管理卫生经济学分析现状:系统综述
该系统综述按PRISMA指南检索Medline、Embase等数据库,纳入3项低级别胶质瘤(LGG)经济学评估研究,用CHEERS清单、Cooper分级和QHES工具评价质量。校正后ICER为3934至9936美元,各研究评估LGG管理不同方面,均具成本效果但异质性大无法合并分析。
要点
- LGG经济学评估证据有限,仅3项研究符合纳入标准。
- 校正后ICER为3934至9936美元,各研究评估的管理方面不同。
- 研究设计质量较高,但效用数据使用质量最欠缺。
核心结论
- 已识别的LGG经济学评估数量有限,但研究设计良好。
- 所评估的干预均被认为具有成本效果,但因干预异质性无法进行合并分析。
- 鉴于价值和成本效果在医疗中的重要性,该领域需要更多证据。
研究设计与样本
- 遵循PRISMA指南的系统综述,检索Medline、Embase、The Central Registration Depository、EconPapers和EconLit中的英文文章。
- 由2名独立评审者筛选结果并提取报告LGG经济学评估的研究数据。
- 采用CHEERS清单、Cooper等(2005)分级量表和Quality of Health Economic Studies(QHES)工具评价每项研究质量。
主要发现
- 共3项研究符合纳入标准,校正后ICER值范围为3934至9936美元。
- 每项研究评估LGG管理的不同方面。
- 按CHEERS清单所有研究均报告质量良好。
- 基于Cooper等分级量表,效用方面的数据使用质量最欠缺。
- QHES工具评分分别为82、92和100。
关键数值与推荐
- 校正后ICER值范围为3934至9936美元(3项纳入研究)。
- QHES研究设计质量评分分别为82、92和100(每项研究)。
- CHEERS清单评价:所有研究报告质量良好。
临床怎么用
- 所评估的LGG管理干预均具成本效果,但证据基础仅3项研究且干预异质,不宜直接合并推广。
- 临床决策参考经济学证据时需注意效用数据质量欠缺这一局限。
局限性
- 仅3项研究符合纳入标准,证据数量有限。
- 各研究评估的干预异质性大,无法进行合并分析。
- 基于Cooper等分级量表,效用方面的数据使用质量最欠缺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Health economic analyses help determine the value of a medical intervention by assessing the costs and outcomes associated with it. The objective of this study was to assess the level of evidence in economic evaluations for low-grade glioma (LGG) management. METHODS: Following the PRISMA guidelines, we conducted a systematic review of English articles in Medline, Embase, The Central Registration Depository, EconPapers, and EconLit. The results were screened, and data were extracted by 2 independent reviewers for studies reporting economic evaluations for LGG. The quality of each study was evaluated using the CHEERS (Consolidated Health Economic Evaluation Reporting Standards) checklist, the hierarchy scale developed by Cooper et al. (2005), and the Quality of Health Economic Studies instrument. RESULTS: Three studies met our inclusion criteria. The adjusted incremental cost-effectiveness ratio (ICER) values for the included studies ranged from $3934 to $9936, but each evaluated a different aspect of LGG management. All had a good quality of reporting per the CHEERS checklist. Based on the Cooper et al. hierarchy scale, the quality of data use was lacking most for utilities. The quality of study design was scored as 82, 92, and 100 for each study using the Quality of Health Economic Studies instrument. CONCLUSIONS: Although a limited number of economic evaluations were identified, the studies evaluated here were well designed. The interventions assessed were all considered cost-effective, but pooled analysis was not possible because of heterogeneity in the interventions assessed. Given the importance of value and cost-effectiveness in medical care, more evidence is needed in this area.
引用
- Tuohy K, Fernandez A, Hamidi N, et al. Current State of Health Economic Analyses for Low-Grade Glioma Management: A Systematic Review. World Neurosurg. 2021. PMID: 34087462. doi:10.1016/j.wneu.2021.05.112
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。